A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Parabilis Medicines, Inc.
AstraZeneca
Merck Sharp & Dohme LLC
Incyte Corporation
National Cancer Institute (NCI)
Sanofi